Get the app
US › Healthcare

Coya Therapeutics, Inc. Common Stock (COYA)

US · Healthcare · Biotechnology

$4.76+6.73%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$243,745
Revenue YoY
+49.0%
Net profit
$-6.6M
EPS
$-0.28
EPS estimate
$-0.36
Net margin
-2,723.4%

EPS came in at -0.28 against a street estimate of -0.36 — a beat of 22.2%.

Key statistics

Market cap
$104.6M
Forward P/E
0.0
P/B
2.52
Book value
$1.84
EPS (TTM)
$-1.03
52-week high
$7.75
52-week low
$3.71
50-day MA
$4.66
200-day MA
$4.82
Beta
0.62

Analyst view

Analysts rate Coya Therapeutics, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $15.21.

Shareholding

Insiders
14.69%
Institutions
33.24%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC3.60%
Alyeska Investment Group, L.P.3.41%
AIGH Capital Management, LLC2.69%
CM Management, LLC1.60%
Private Management Group Inc1.57%
Geode Capital Management, LLC0.99%
Marshall Wace Asset Management Ltd0.96%
Prosight Management, LP0.72%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Coya Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.